1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

COVID-19 Antibody Tests Being Abused To Falsely Diagnose Coronavirus Cases, FDA Says

Agency revises its 16 March guidance, forwards cases to enforcement branch to stop misuses

 
• By Sue Darcey

A negative COVID-19 antibody or serology test, even when authorized by FDA, is a poor indicator of whether an individual currently has or is completely immune from contracting coronavirus, the agency said on 4 May, issuing an updated guidance to drive the lesson home.

FDA entrance sign 2016
FDA recently warned commercial test manufacturers against inappropriate uses of COVID-19 antibody tests

Some manufacturers are inappropriately marketing their COVID-19 antibody/serology tests for diagnostic use, US Food and Drug Administration officials said at a 4 May press briefing. The realization has prompted the agency to revise its immediately-in-effect guidance of 16 March for both diagnostic and antibody tests.

While high-quality antibody tests can provide information about a population’s exposure to COVID-19, “the antibody tests may not be used as the sole basis for diagnosing cases of coronavirus,” FDA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.